Skip to main content

Wabash Announces Third Quarter 2025 Results

Quarterly revenue of $382 million – Softer than expected demand, particularly in our Truck Body business, led to revenue coming in below our guidance range. Parts & Services generated positive revenue growth sequentially and year-over-year. GAAP operating income of $58 million or Non-GAAP adjusted operating loss of $24 million; Excludes impact of $81 million gain related to the settlement of the Missouri legal verdict. Quarterly GAAP EPS of $0.97 or Non-GAAP adjusted EPS of $(0.51). Missing Expectations due to revenue miss and operational inefficiencies associated with lower than expected volumes. Total backlog of $829 million ending Q3; Market environment continues to be challenging as economic concerns and uncertainty remain. 2025 revenue outlook reduced to $1.5B, Non-GAAP adjusted EPS outlook reduced to $(2.00), excluding...

Continue reading

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026 RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026 Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026 $1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended...

Continue reading

Donegal Group Inc. Announces Third Quarter and First Nine Months of 2025 Results

MARIETTA, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) — Donegal Group Inc. (NASDAQ: DGICA) and (NASDAQ: DGICB) today reported its financial results for the third quarter and first nine months of 2025. Significant Items for third quarter of 2025 (all comparisons to third quarter of 2024):Net premiums earned decreased 3.4% to $229.8 million Combined ratio of 95.9%, compared to 96.4% Net income of $20.1 million, or 55 cents per diluted Class A share, compared to $16.8 million, or 51 cents per diluted Class A share Net income included after-tax net investment gains of $1.0 million, or 3 cents per diluted Class A share, compared to $1.5 million, or 5 cents per diluted Class A share Annualized return on average equity of 13.0%, compared to 13.4% Book value per share of $17.14 at September 30, 2025, compared to $15.22Financial Summary                         Three...

Continue reading

Kimco Realty® Announces Third Quarter 2025 Results

– Achieves Record Leased-to-Economic Occupancy Spread –– New High in Small Shop Occupancy –– 4% Increase to Cash Dividend on Common Shares –– Raises 2025 Outlook Range – JERICHO, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) — Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the third quarter ended September 30, 2025. For the three months ended September 30, 2025 and 2024, Net income available to the company’s common shareholders (“Net income”) per diluted share was $0.19 for both periods. HighlightsProduced Funds From Operations(1) (“FFO”) of $0.44 per diluted share. Grew pro-rata portfolio occupancy to 95.7%, up 30 basis points sequentially. Reached an...

Continue reading

XPO Reports Third Quarter 2025 Results

GREENWICH, Conn., Oct. 30, 2025 (GLOBE NEWSWIRE) — XPO (NYSE: XPO) today announced its financial results for the third quarter 2025. The company reported diluted earnings per share of $0.68, compared with $0.79 for the same period in 2024, and adjusted diluted earnings per share of $1.07, compared with $1.02 for the same period in 2024.Third Quarter 2025 Summary Results                                     Three Months Ended September 30,    Revenue   Operating Income (Loss)(1)(in millions)     2025     2024   Change %     2025       2024     Change %North American Less-Than-Truckload Segment   $ 1,255   $ 1,251   0.3 %   $ 208     $ 188     10.6 %European Transportation Segment     857     803   6.7 %     (2 )     6     NMCorporate     –     –   0.0 %     (42 )     (18 )   133.3 %Total   $ 2,111   $ 2,053   2.8 %   $ 164     $ 176     -6.8 %                                     Adjusted...

Continue reading

Scorpio Tankers Inc. Announces Financial Results for the Third Quarter of 2025 and an Increase to Its Quarterly Dividend

MONACO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE: STNG) (“Scorpio Tankers” or the “Company”) today reported its results for the three months ended September 30, 2025. The Company also announced that its board of directors (the “Board of Directors”) has declared a quarterly cash dividend on its common shares of $0.42 per share. Results for the three months ended September 30, 2025 and 2024 For the three months ended September 30, 2025, the Company had net income of $84.5 million, or $1.81 basic and $1.73 diluted earnings per share. For the three months ended September 30, 2025, the Company had adjusted net income (see Non-IFRS Measures section below) of $72.7 million, or $1.56 basic and $1.49 diluted earnings per share, which excludes from net income (i) a $12.7 million, or...

Continue reading

CSW Industrials Reports Record Results for Fiscal 2026 Second Quarter and First Half

DALLAS, Oct. 30, 2025 (GLOBE NEWSWIRE) — CSW Industrials, Inc. (NYSE: CSW or the “Company”) today reported record results for the fiscal 2026 second quarter period ended September 30, 2025. Fiscal 2026 Second Quarter Highlights (comparisons to fiscal 2025 second quarter)Total revenue increased 21.5% to a quarter record of $277.0 million, driven by acquisitions during the last twelve months Net income attributable to CSW of $40.7 million, increased 12.8% to a second quarter record, compared to $36.1 million Earnings per diluted share (“EPS”) of $2.41, increased 6.7% when compared to $2.26 Adjusted EPS of $2.96, excluding the amortization of acquisition-related intangible assets and transaction expenses, increased 15.2% when compared to $2.57 Adjusted EBITDA grew 19.9% to a quarter record of $72.9 million Paid...

Continue reading

FirstCash Reports Record Third Quarter Operating Results Across All Segments; Recent U.K. Acquisition Drives Additional Revenue and Earnings Growth; Declares Quarterly Cash Dividend and Authorizes New $150 Million Share Repurchase Plan

FORT WORTH, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) — FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS), the leading international operator of more than 3,300 retail pawn stores, today announced record revenue and earning results for the three and nine month periods ended September 30, 2025. The Company also announced that the Board of Directors declared a quarterly cash dividend of $0.42 per share, which will be paid in November 2025, and authorized a new $150 million share repurchase plan. Mr. Rick Wessel, chief executive officer, stated, “FirstCash’s third quarter operating results were outstanding, evidenced by accelerating revenue growth, strong margins and continued earnings growth in both the U.S. and Latin American pawn segments coupled with a strong partial quarter contribution from the recently acquired...

Continue reading

Amneal Reports Third Quarter 2025 Financial Results

‒ Q3 2025 Net Revenue of $785 million; GAAP Net Income of $2 million; Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million; Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ‒ BRIDGEWATER, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2025. “Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ongoing evolution of our portfolio. CREXONT® for Parkinson’s disease and other key branded products continue to drive Specialty growth, complemented by the launch this month of BREKIYA® in the migraine space. At the same time, our Affordable Medicines segment is entering a significant new product launch...

Continue reading

LXP Industrial Trust Reports Third Quarter 2025 Results

Board Authorizes 3.7% Dividend Increase WEST PALM BEACH, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) — LXP Industrial Trust (“LXP”) (NYSE: LXP), a real estate investment trust focused on Class A warehouse and distribution real estate investments, today announced results for the quarter ended September 30, 2025. Third Quarter 2025 HighlightsRecorded Net Income attributable to common shareholders of $34.6 million, or $0.12 per diluted common share. Generated Adjusted Company Funds From Operations available to all equityholders – diluted (“Adjusted Company FFO”) of $46.7 million, or $0.16 per diluted common share. Sold two vacant development projects totaling 2.1 million square feet to a user buyer for $175 million, representing a 20% premium over the gross book value. Increased the Stabilized Portfolio leased percentage to 96.8%....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.